Active not recruiting
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
J2T-DM-KGAB - ClinicalTrials.gov - NCT04146363
The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis.
How long will I be in the trial?
The study will last about 66 weeks and may include up to 20 visits.
Active not recruiting
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
J2T-DM-KGAB - ClinicalTrials.gov - NCT04146363
The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis.
How long will I be in the trial?
The study will last about 66 weeks and may include up to 20 visits.
Key Requirements
Age :
12+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
12+
Sex
All
Participants must
Participant must be an adult (≥18 years) or adolescent (12 to <18years) and weighing ≥40kg
Participants must have atopic dermatitis that has been present for at least one year
Participants must have ≥10% body surface area (BSA) of atopic dermatitis involvement
Participants must have had an inadequate response to treatment with topical medications and must not have had treatment with the medications dupilumab, tralokinumab or lebrikizumab
Participants must NOT
Participant must not have used certain topical atopic dermatitis treatment within 1 week
Participants must not have received a vaccine within 12 weeks of starting the study
Participants must not have hepatitis
Participants must not have a history of HIV
Participants must not have a history of cancer within 5 years
Women must not be pregnant, breastfeeding or plan to become pregnant during the study
Trial Summary
Conditions the trial is for
Pediatric Atopic Dermatitis (Eczema), Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
yes
Enrollment Goal
400
Trial Dates
September 2019 - May 2022
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
12+
Sex
All
Participants must
Participant must be an adult (≥18 years) or adolescent (12 to <18years) and weighing ≥40kg
Participants must have atopic dermatitis that has been present for at least one year
Participants must have ≥10% body surface area (BSA) of atopic dermatitis involvement
Participants must have had an inadequate response to treatment with topical medications and must not have had treatment with the medications dupilumab, tralokinumab or lebrikizumab
Participants must NOT
Participant must not have used certain topical atopic dermatitis treatment within 1 week
Participants must not have received a vaccine within 12 weeks of starting the study
Participants must not have hepatitis
Participants must not have a history of HIV
Participants must not have a history of cancer within 5 years
Women must not be pregnant, breastfeeding or plan to become pregnant during the study
Trial Summary
Conditions the trial is for
Pediatric Atopic Dermatitis (Eczema), Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
yes
Enrollment Goal
400
Trial Dates
September 2019 - May 2022
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Resources
